To the Editor:—
A simple and safe method of managing metastatic osteoblastic prostatic cancer with sodium fluoride is presented. Desperation and frustration led to a trial of this drug in patients with bone lesions refractory to radiotherapy and no longer responsive to hormonal therapy. There was little if any rationale for its use other than for its success in the osteoblastic lesions of Paget's disease (the radiographic appearance of which is often indistinguishable from the metastatic bone lesions of prostatic carcinoma), its questionable cytotoxic effect, and its documented safety of administration over a prolonged time. Even at this early date we are encouraged by results of fluoride treatment of osteolytic metastases of breast, lung, and colon. It is far too early to comment on bone changes, either radiographically or histologically, since they may take years to develop if they develop at all.The exact mechanism of fluoride action on bone
Scott WP. Fluoride Treatment of Bone Pain in Cancer of the Prostate. JAMA. 1967;202(7):664. doi:10.1001/jama.1967.03130200150039
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: